[EN] SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROARYLE SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
申请人:SUNSHINE LAKE PHARMA CO LTD
公开号:WO2017048675A1
公开(公告)日:2017-03-23
The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR
申请人:Zhuhai Yufan Biotechnologies Co., Ltd
公开号:EP4006028A1
公开(公告)日:2022-06-01
The present invention provides a compound of general formula I, and a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug, a solvate and a deuterated compound thereof, wherein the compound is an IRAK4 kinase inhibitor, and can be used for preventing and/or treating diseases related to IRAK4, such as autoimmune diseases, inflammatory diseases, cancers, heteroimmune diseases, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.
[EN] IRAK4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR<br/>[FR] INHIBITEUR DE LA KINASE IRAK4 ET SON PROCÉDÉ DE PRÉPARATION<br/>[ZH] 一种IRAK4激酶抑制剂及其制备方法
The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.